Comparison of Continuous Glucose Monitoring in Cystic Fibrosis Patients With or Without Pancreatic Exocrine Insufficiency

Abstract

This study aimed to compare continuous glucose monitoring (CGM) in cystic fibrosis (CF) according to pancreatic exocrine status.

CGM and oral glucose tolerance testing (OGTT) were realized annually over five years in people with CF (pwCF) aged≥10 years without cystic fibrosis-related diabetes (CFRD). CGM parameters in patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and newly diagnosed CFRD were compared according to presence of pancreatic sufficiency (PS) or insufficiency (PI).

Overall, 547 OGTTs and 501 CGMs were performed in 147 CF patients, comprising 122 PI and 25 PS. In PS patients, 84% displayed NGT, 12% IGT, and 4% CFRD vs. 58%, 32%, and 10% (p=0.05) in PI. Among participants displaying normal OGTT, time in glucose range (70–140 mg/dl) was significantly increased, 97% (93, 99) vs. 92% (85, 96), p<0.001, and time above glucose range > 140 mg/dl significantly decreased, 1% (0, 2) % vs. 6% (2, 13), in patients with PS compared to those with PI. No significant differences were highlighted in patients with IGT.

CGM revealed significant different glucose tolerance abnormalities in PI versus PS, which were undetected by standard 2-hour OGTT glucose.

Key words

secondary diabetes - glucose intolerance - pancreatic exocrine status - glucose monitoring

Publication History

Received: 15 December 2021

Accepted: 10 March 2022

Accepted Manuscript online:
10 March 2022

Article published online:
03 May 2022

• References

• 1 Moran A, Dunitz J, Becker D. et al. Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis-Related Diabetes. Diabetes Care 2010; 33: 2677-2683
• 2 Gibson-Corley KN, Meyerholz DK, Engelhardt JF. Pancreatic Pathophysiology in Cystic Fibrosis. The Journal of Pathology 2016; 238: 311-320
• 3 Couce M, O’Brien TD, Moran A. et al. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1267-1272
• 4 Moran A, Brunzell C, Cohen RC. et al. Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697-2708
• 5 Hardin DS, Grilley K, Baron B. et al. Accelerated Red Blood Cell Turnover Can Invalidate the Use of Hemoglobin A1c as a Diagnostic Test for Cystic Fibrosis Related Diabetes. Pediatric Research 1999; 45: 90A-90A
• 6 Walshaw M. Routine OGTT screening for CFRD – no thanks. Journal of the Royal Society of Medicine 2009; 102: 40-44
• 7 Scheuing N, Holl RW, Dockter G. et al. High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study. Multicenter Study. PLoS One 2014; 9: e112578
• 8 Leclercq A, Gauthier B, Rosner V. et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. Journal of Cystic Fibrosis 2014; 13: 478-484
• 9 Prentice BJ, Chelliah A, Ooi CY. et al. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. Journal of Cystic Fibrosis 2020; 19: 305-309
• 10 Potter KJ, Boudreau V, Shohoudi A. et al. Influence of pre-diabetic and pancreatic exocrine states on pulmonary and nutritional status in adults with Cystic Fibrosis. Journal of Cystic Fibrosis. 2020 S1569199320309322
• 11 O'Riordan S, Hindmarsh P, Hill NR. et al. Validation of Continuous Glucose Monitoring in Children and Adolescents with Cystic Fibrosis: A prospective cohort study. Diabetes Care 2009; 32: 1020-1022
• 12 Chan CL, Larson Ode K, Granados A. et al. Continuous glucose monitoring in cystic fibrosis – A practical guide. Journal of Cystic Fibrosis 2019; 18: S25-S31
• 13 Wilschanski M, Durie PR. Pathology of pancreatic and intestinal disorders in cystic fibrosis. Journal of the Royal Society of Medicine 1998; 91: 40-49
• 14 Kerem E, Corey M, Kerem BS. et al. The Relation between Genotype and Phenotype in Cystic Fibrosis – Analysis of the Most Common Mutation (ΔF 508). New England Journal of Medicine 1990; 323: 1517-1522
• 15 Gaskin K, Gurwitz D, Durie P. et al. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. The Journal of Pediatrics 1982; 100: 857-862
• 16 Sheikh S, Gudipaty L, De Leon DD. et al. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes 2017; 66: 134-144
• 17 Brodsky J, Dougherty S, Makani R. et al. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011; 34: 292-295
• 18 Bonhoure A, Potter KJ, Colomba J. et al. Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis. Diabetologia 2021; 64: 1332-1341
• 19 Chan CL, Vigers T, Pyle L. et al. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. Journal of Cystic Fibrosis 2018; 17: 783-790
• 20 Yi Y, Norris AW, Wang K. et al. Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine 2016; 194: 974-980
• 21 Shah VN, DuBose SN, Li Z. et al. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. The Journal of Clinical Endocrinology and Metabolism 2019; 104: 4356-4364
• 22 Misgault B, Chatron E, Reynaud Q. et al. Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients. Journal of Cystic Fibrosis 2020; 19: 712-716